A Safety Study Evaluating N6022 in Multiple-Ascending Doses in Healthy Subjects

NCT ID: NCT01339897

Last Updated: 2015-01-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 25 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-04-30
• Study Completion Date: 2011-08-31

Brief Summary

This Phase 1 study will evaluate multiple doses across a range that has been found to be effective in mouse models of asthma and safe in one Phase 1 clinical trial. It is intended to provide evidence of the tolerability of multiple doses as well as provide information on the Pharmacokinetic (PK) and metabolism of N6022 in humans.

Detailed Description

This is a double-blind, randomized, placebo-controlled, multiple ascending dose study, in at least three ascending cohorts. Twenty-four subjects will be enrolled initially in the first three cohorts, with up to 40 subjects to be enrolled overall if additional cohorts are required to reach the maximum tolerated dose (MTD). The cohorts will be enrolled in two groups of 4 each with approximately 7 days between groups to conduct safety monitoring committee review for approval to proceed to the second group in the cohort. Eight subjects will be enrolled per cohort, randomized 3:1 to N6022: placebo. Each subject will undergo screening (Day -28 to Day -2) and, if eligible, they will be instructed to begin a low-nitrate diet on Day -4. Subjects will return to the clinical site on Day -1, and eligibility will be reconfirmed. Eligible subjects will receive a dose of investigational medicinal product ([IMP], N6022 or placebo) by intravenous (IV) infusion on study Days 1 through 7 and will be followed for safety, PK, and PD until discharge on the morning of Day 8. Subjects will return to the clinic for a follow-up visit on Day 15 (± 1 day) and will be contacted via telephone on Day 28 (± 1 day) for the end-of-study safety follow-up visit. Participation of an individual subject may last approximately 56 days from the time of screening until the end-of-study follow-up visit.

A Safety Monitoring Committee (SMC) will review the safety data in each cohort after the Day 15 Follow-up visit, before proceeding to the next ascending dose cohort, modifying the dose, repeating a dose, or stopping the study according to the stopping rules outlined in the protocol.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

5 mg/N6022

Injectable formulation, given at doses per cohort of 5 mg given QD each day over 7 days.

Group Type: ACTIVE_COMPARATOR

5 mg/N6022

Intervention Type: DRUG

Intravenous formulation, given at doses of 5 mg once each day over 7 days.

Placebo

Injectable formulation normal saline

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Same administration procedures as active

10mg/N6022

Injectable formulation, given at doses of 10 mg given QD each day over 7 days.

Group Type: ACTIVE_COMPARATOR

10mg/N6022

Intervention Type: DRUG

Intravenous formulation given at doses of 10 mg once each day over 7 days.

20mg/N6022

Injectable formulation, given at doses per cohort of 20 mg given QD each day over 7 days.

Group Type: ACTIVE_COMPARATOR

20mg/N6022

Intervention Type: DRUG

Intravenous formulation given at doses of 20 mg once each day over 7 days.

Interventions

5 mg/N6022

Intravenous formulation, given at doses of 5 mg once each day over 7 days.

Intervention Type: DRUG

Placebo

Same administration procedures as active

Intervention Type: DRUG

10mg/N6022

Intravenous formulation given at doses of 10 mg once each day over 7 days.

Intervention Type: DRUG

20mg/N6022

Intravenous formulation given at doses of 20 mg once each day over 7 days.

Intervention Type: DRUG

Other Intervention Names

N6022; GSNOR Inhibitor; Normal Saline; N6022; GSNOR Inhibitor; N6022; GSNOR Inhibitor

Eligibility Criteria

Inclusion Criteria

1. Subject is healthy, determined by pre-study medical evaluation (medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory evaluations

2. Subject is a non-smoker (or other nicotine user) as determined by history (no nicotine use over the past year) and a negative urine cotinine test at screening and Day 1.

3. Subject has a body weight > 50 kg and BMI between 19.5 and 29.5 kg/m2, inclusive, at screening.

4. Subject has systolic BP > 90 mmHg and diastolic BP > 50 mmHg at screening or Day-1.

Exclusion Criteria

1. Subject has clinically significant history or evidence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunological, or psychiatric disorder(s) as determined by the investigator or designee.

2. Subject is a current alcohol abuser and/or has a history of illicit drug abuse within six months of entry.

3. Subject has donated blood (> 500 mL) or blood products within 56 days prior to Day -1.

4. Subject has a history of bleeding disorders (i.e., severe hemorrhage, melena, rectal bleeding, nosebleeds, bruising, etc.).

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Nivalis Therapeutics, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ronald Goldwater, MDCM, MSc(A)

Role: PRINCIPAL_INVESTIGATOR

Parexel

Locations

Parexel International

Baltimore, Maryland, United States

Countries

United States

Other Identifiers

N6022-1H1-03

Identifier Type: -

Identifier Source: org_study_id